Evaluation of the rational prescription of linezolid, the prevalence of thrombocytopenia and major drug interactions in patients with cardiovascular diseases: are there any cautions?
Journal of Pharmacy & Pharmaceutical Sciences · 2024
DOI: 10.3389/jpps.2024.13343 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy & Pharmaceutical Sciences, 2024. Verfasst von Mehrnoush Dianatkhah und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Faculty of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran. Hauptthemen laut MEDLINE: Linezolid, Thrombocytopenia, Cardiovascular Diseases, Drug Interactions. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The present study evaluated the rational prescription of linezolid, the prevalence of thrombocytopenia, and major drug interactions in patients with cardiovascular diseases. We conducted a retrospective cross-sectional study on linezolid-treated patients at Shahid Chamran Heart Hospital in Isfahan from March 21, 2021, to March 20, 2022. Our research involved 132 patients who received linezolid. We reported 43.18% of linezolid prescriptions as irrational. Linezolid-induced thrombocytopenia is more common than previous studies, with a prevalence of 47.9%. We found a significant relationship between thrombocytopenia and the concomitant use of aspirin. The duration of treatment was identified as predicting factor for linezolid-induced thrombocytopenia. Moreover, the prevalence of interactions in the X and D categories was determined. Serotonergic and catecholamine medications were associated with 56.1% and 47.7% medication interactions, respectively. Our study found a high prevalence of linezolid-induced thrombocytopenia among patients with cardiovascular diseases. Based on this study, physicians should focus more closely on prescribing linezolid to patients with cardiovascular diseases. In addition to following rational antibiotic use, this susceptible group is also at an elevated risk of side effects (thrombocytopenia) and medication interactions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, Faculty of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran.
- Chamran Cardiovascular Medical and Research Hospital, Isfahan, Iran.
- Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran.
- Department of Cardiac Surgery, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Zitieren
APA
Dianatkhah, M., Salami, H., Soltani, R., & Hosseini, A. (2024). Evaluation of the rational prescription of linezolid, the prevalence of thrombocytopenia and major drug interactions in patients with cardiovascular diseases: are there any cautions?. Journal of Pharmacy & Pharmaceutical Sciences. https://doi.org/10.3389/jpps.2024.13343
Vancouver
Dianatkhah M, Salami H, Soltani R, Hosseini A. Evaluation of the rational prescription of linezolid, the prevalence of thrombocytopenia and major drug interactions in patients with cardiovascular diseases: are there any cautions?. Journal of Pharmacy & Pharmaceutical Sciences. 2024. doi:10.3389/jpps.2024.13343
BibTeX
@article{Dianatkhah2024,
author = {Dianatkhah, Mehrnoush and Salami, Hamed and Soltani, Rasool and Hosseini, Alireza},
title = {Evaluation of the rational prescription of linezolid, the prevalence of thrombocytopenia and major drug interactions in patients with cardiovascular diseases: are there any cautions?},
journal = {Journal of Pharmacy & Pharmaceutical Sciences},
year = {2024},
doi = {10.3389/jpps.2024.13343}
}
EUVIMED